These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 25994761)

  • 1. Quantitative detection of DNMT3A R882H mutation in acute myeloid leukemia.
    Berenstein R; Blau IW; Suckert N; Baldus C; Pezzutto A; Dörken B; Blau O
    J Exp Clin Cancer Res; 2015 May; 34(1):55. PubMed ID: 25994761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two novel methods for rapid detection and quantification of DNMT3A R882 mutations in acute myeloid leukemia.
    Mancini M; Hasan SK; Ottone T; Lavorgna S; Ciardi C; Angelini DF; Agostini F; Venditti A; Lo-Coco F
    J Mol Diagn; 2015 Mar; 17(2):179-84. PubMed ID: 25554589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy-related acute myeloid leukemia developing 14 years after allogeneic hematopoietic stem cell transplantation, from a persistent R882H-DNMT3A mutated clone of patient origin.
    Martín I; Navarro B; Villamón E; Solano C; Serrano A; Calabuig M; Amat P; Domingo F; Abellán R; García F; Olivares MD; Chaves FJ; Tormo M; Hernández-Boluda JC
    Exp Mol Pathol; 2018 Aug; 105(1):139-143. PubMed ID: 30017658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent DNMT3A mutation burden in DNMT3A mutated adult cytogenetically normal acute myeloid leukemia patients in long-term remission.
    Sun Y; Shen H; Xu T; Yang Z; Qiu H; Sun A; Chen S; Wu D; Xu Y
    Leuk Res; 2016 Oct; 49():102-7. PubMed ID: 27626217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations.
    Xu Y; Sun Y; Shen H; Ding L; Yang Z; Qiu H; Sun A; Chen S; Wu D
    Am J Hematol; 2015 Nov; 90(11):992-7. PubMed ID: 26223865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.
    Ahn JS; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):61-70. PubMed ID: 26234722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution of mutations in DNMT3A gene and the suitability of mutations in R882 codon for MRD monitoring in patients with AML.
    Jeziskova I; Musilova M; Culen M; Foltankova V; Dvorakova D; Mayer J; Racil Z
    Int J Hematol; 2015 Nov; 102(5):553-7. PubMed ID: 26290145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNMT3A R882 mutations in patients with cytogenetically normal acute myeloid leukemia and myelodysplastic syndrome.
    El Ghannam D; Taalab MM; Ghazy HF; Eneen AF
    Blood Cells Mol Dis; 2014; 53(1-2):61-6. PubMed ID: 24512939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence of DNMT3A mutations at long-term remission in adult patients with AML.
    Pløen GG; Nederby L; Guldberg P; Hansen M; Ebbesen LH; Jensen UB; Hokland P; Aggerholm A
    Br J Haematol; 2014 Nov; 167(4):478-86. PubMed ID: 25371149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia.
    Bhatnagar B; Eisfeld AK; Nicolet D; Mrózek K; Blachly JS; Orwick S; Lucas DM; Kohlschmidt J; Blum W; Kolitz JE; Stone RM; Bloomfield CD; Byrd JC
    Br J Haematol; 2016 Oct; 175(2):226-236. PubMed ID: 27476855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of DNMT3a gene mutations in acute myelogenous leukemia].
    Qiao C; Sun C; Zhang SJ; Qian SX; Qian XF; Miao KR; Zhu HY; Hong M; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):303-7. PubMed ID: 21518476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel impact of the DNMT3A R882H mutation on GSH metabolism in a K562 cell model established by TALENs.
    Yang L; Liu Y; Zhang N; Ding X; Zhang W; Shen K; Huang L; Zhou J; Cui S; Zhu Z; Hu Z; Xiao M
    Oncotarget; 2017 May; 8(18):30395-30409. PubMed ID: 28418922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.
    Thol F; Damm F; Lüdeking A; Winschel C; Wagner K; Morgan M; Yun H; Göhring G; Schlegelberger B; Hoelzer D; Lübbert M; Kanz L; Fiedler W; Kirchner H; Heil G; Krauter J; Ganser A; Heuser M
    J Clin Oncol; 2011 Jul; 29(21):2889-96. PubMed ID: 21670448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.
    Renneville A; Boissel N; Nibourel O; Berthon C; Helevaut N; Gardin C; Cayuela JM; Hayette S; Reman O; Contentin N; Bordessoule D; Pautas C; Botton Sd; Revel Td; Terre C; Fenaux P; Thomas X; Castaigne S; Dombret H; Preudhomme C
    Leukemia; 2012 Jun; 26(6):1247-54. PubMed ID: 22289988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers.
    Russler-Germain DA; Spencer DH; Young MA; Lamprecht TL; Miller CA; Fulton R; Meyer MR; Erdmann-Gilmore P; Townsend RR; Wilson RK; Ley TJ
    Cancer Cell; 2014 Apr; 25(4):442-54. PubMed ID: 24656771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of DNMT3A mutations in patients with acute myeloid leukemia.
    Ibrahem L; Mahfouz R; Elhelw L; Abdsalam EM; Soliman R
    Blood Cells Mol Dis; 2015 Jan; 54(1):84-9. PubMed ID: 25172541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative examination of various PCR-based methods for DNMT3A and IDH1/2 mutations identification in acute myeloid leukemia.
    Berenstein R; Blau IW; Kar A; Cay R; Sindram A; Seide C; Blau O
    J Exp Clin Cancer Res; 2014 May; 33(1):44. PubMed ID: 24887327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia.
    Marková J; Michková P; Burčková K; Březinová J; Michalová K; Dohnalová A; Maaloufová JS; Soukup P; Vítek A; Cetkovský P; Schwarz J
    Eur J Haematol; 2012 Feb; 88(2):128-35. PubMed ID: 21967546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNMT3A R882H mutation drives daunorubicin resistance in acute myeloid leukemia via regulating NRF2/NQO1 pathway.
    Chu X; Zhong L; Dan W; Wang X; Zhang Z; Liu Z; Lu Y; Shao X; Zhou Z; Chen S; Liu B
    Cell Commun Signal; 2022 Oct; 20(1):168. PubMed ID: 36303144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia.
    Wakita S; Marumo A; Morita K; Kako S; Toya T; Najima Y; Doki N; Kanda J; Kuroda J; Mori S; Satake A; Usuki K; Ueki T; Uoshima N; Kobayashi Y; Kawata E; Nakayama K; Nagao Y; Shono K; Shibusawa M; Tadokoro J; Hagihara M; Uchiyama H; Uchida N; Kubota Y; Kimura S; Nagoshi H; Ichinohe T; Kurosawa S; Motomura S; Hashimoto A; Muto H; Sato E; Ogata M; Mitsuhashi K; Ando J; Tashiro H; Sakaguchi M; Yui S; Arai K; Kitano T; Miyata M; Arai H; Kanda M; Itabashi K; Fukuda T; Kanda Y; Yamaguchi H
    Cancer Sci; 2023 Apr; 114(4):1297-1308. PubMed ID: 36610002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.